Ramucirumab DP

BIOLOGICAL2 trials

Sponsors

Eli Lilly and Company

Conditions

Breast CancerCarcinoma of Renal PelvisCarcinoma of UreterCarcinoma of Urinary TractUrethral Carcinoma

Phase 2

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

CompletedNCT01234402

Eli Lilly and CompanyBreast Cancer

Start: 2011-03-31End: 2017-07-31Updated: 2019-08-14

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

CompletedNCT01282463

Eli Lilly and CompanyCarcinoma of Renal Pelvis, Carcinoma of Ureter, Carcinoma of Urinary Tract +1

Start: 2011-04-30End: 2015-03-31Updated: 2019-09-09

Related Papers

Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.

Journal of Clinical Oncology2015-03-0115 citations